Moderna Ties Legal Chief's Retirement Payments To Litigation, Including Up To $5.5 Million
The agreement preserves salary and equity vesting through retirement and provides $1.6 million in severance.
Moderna, which develops mRNA medicines and vaccines, agreed Friday to retirement terms for Chief Legal Officer Shannon Thyme Klinger that include up to $5.5 million tied to litigation outcomes. The company's SEC filing also outlined a separate potential $2.5 million payment if Moderna prevails in another group of disputes.
Two Sets Of Litigation Stakes
The $5.5 million payment depends on the results of Moderna's litigation involving Pfizer, BioNTech and related parties. The agreement covers both current cases and any related future proceedings.
For the $2.5 million payment, Moderna must prevail once all current and related future proceedings against Arbutus Biopharma and Genevant Sciences, its litigation opponents, have concluded. Both payments remain subject to the agreement's terms.
Those disputes sit alongside a substantial legal cost: Moderna recorded a $950 million charge in the first quarter of 2026.
Salary, Severance And Health Coverage
Klinger is scheduled to remain employed until March 31, 2027, and will transfer her duties as Moderna requests. The company can set an earlier date for her departure from all officer positions.
Through retirement, she will retain her current salary and benefits, and her outstanding equity awards will continue vesting. Her eligibility for a 2026 performance bonus uses her target bonus multiplied by the corporate performance factor set by Moderna's board.
The agreement provides $1.6 million in severance, representing twelve months of base salary plus her current annual target bonus. Moderna will pay it in roughly equal biweekly installments over the twelve months after retirement, subject to the agreement's terms.
Moderna will also cover premiums for continued health insurance through September 30, 2028. That coverage ends earlier if Klinger becomes eligible for a subsequent employer's health plan or loses eligibility for continued coverage.
Vaccine Sales Outlook Improves
Moderna's third-quarter revenue grew 29%, and it reported $162 million in net income under standard accounting. Management raised its forecast for full-year revenue growth to 15%-25%, from up to 10%.
The company sells the COVID vaccines Spikevax and mNEXSPIKE, plus mRESVIA against respiratory syncytial virus, or RSV. Its 2025 revenue totaled $1.9 billion, largely from COVID vaccine sales.
Its development work extends beyond those products: Moderna has 35 therapeutic and vaccine programs, six in late-stage development, across infectious diseases, cancer and rare diseases. It works with Merck on an individualized cancer therapy and Recordati on a rare disease treatment, and operates a global manufacturing network with facilities it built and manages in the UK, Canada and Australia.
Klinger's scheduled retirement on March 31, 2027, sets the start of her severance payments; the additional litigation payments depend on the outcomes of the proceedings.
Sources
- 8-K Filing — Moderna, Inc. (MRNA) — SEC EDGAR
- Moderna Earnings: Raising Fair Value Estimate as Steadying Demand for Respiratory Vaccines Supports Strong Quarter | Morningstar — morningstar.com